Premium
Ureteral stent placement and BK viremia in kidney transplant recipients
Author(s) -
Kayler L.,
Zendejas I.,
Schain D.,
Magliocca J.
Publication year - 2013
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12051
Subject(s) - viremia , medicine , bk virus , stent , kidney transplantation , kidney , urology , transplantation , gastroenterology , surgery , immunology , virus
BK virus ( BKV ) infection is an important cause of kidney transplant dysfunction. A possible association of double‐J ureteral stent placement and BK viremia has been suggested in previous studies; however, risk factors for BK are incompletely understood. We aimed to determine if stent placement is an independent risk factor for BK viremia. Methods Data were collected on consecutive kidney‐only transplant recipients between D ecember 1, 2006 and J une 30, 2010. All patients had at least 12 months of follow‐up. Results Of 600 consecutive kidney transplants, BK viremia within the first post‐transplant year was detected in 93 patients (15.5%); in 70 of these cases, the peak BKV polymerase chain reaction was ≥10,000 copies/mL. By multivariate analysis, significant risk factors for BK viremia were recipient age ( P = 0.02) and stent placement ( P = 0.03). Stents were placed in 49.2% and removed at a median of 46 days (range: 11–284) post transplantation; removals occurred within 0–30, 30–60, 60–90, 90–120, 120–150, and >150 days post transplantation in 18.4%, 67.2%, 10.5%, 2.4%, 1.0%, and 0.3% of cases, respectively. No association was found of BK viremia with stent duration >46 days ( P = 0.70) or by the 6‐level groupings ( P = 0.92). Conclusions Although we observed a significant association of BK viremia with stent placement, no dose‐dependent effect was seen.